CTXRCitius Pharmaceuticals, Inc.

CTXR Stock Price, Valuation & Chart | Citius Pharmaceuticals, Inc.

Compare

$0.580+0.01 (+1.83%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology CTXR intrinsic value CTXR calculated fair value vs price

Overview Financials Dividends Ratios

CTXR Historical price chart

CTXR Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization6.48M

PE Ratio-0.34

EPS-1.68

Trading Volume209.47K

Today's High/Low0.58/0.56

Dividend Yield0.00

52 Week High/Low2.19/0.47

Shares Outstanding11.17M

CTXR Financial Statement

CTXR Analyst ratings

CTXR Analysis & performance metrics

CTXR Company profile

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective…

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with…

CTXR Management team

Name

Position

Dhananjay G. Wadekar

Senior Vice President of Business Strategy

Ilanit Allen

Vice President of Investor Relations & Corporate Communications

Myron S. Czuczman M.D.

Executive Vice President & Chief Medical Officer

Jaime BartushakCFO

Chief Business Officer & Chief Financial Officer

Kelly Creighton Ph.D.

Executive Vice President of Chemistry, Manufacturing & Controls

Gary F. Talarico

Executive Vice President of Operations

Nikolas Burlew

Executive Vice President of Quality Assurance

Myron Z. Holubiak

Co-Founder & Executive Vice Chairman

Name

Position

Dhananjay G. Wadekar

Senior Vice President of Business Strategy

Ilanit Allen

Vice President of Investor Relations & Corporate Communications

Myron S. Czuczman M.D.

Executive Vice President & Chief Medical Officer

Jaime BartushakCFO

Chief Business Officer & Chief Financial Officer

Kelly Creighton Ph.D.

Executive Vice President of Chemistry, Manufacturing & Controls

Gary F. Talarico

Executive Vice President of Operations

Nikolas Burlew

Executive Vice President of Quality Assurance

Myron Z. Holubiak

Co-Founder & Executive Vice Chairman

Management Team

Dhananjay G. Wadekar

Senior Vice President of Business Strategy

Ilanit Allen

Vice President of Investor Relations & Corporate Communications

Myron S. Czuczman M.D.

Executive Vice President & Chief Medical Officer

Jaime BartushakCFO

Chief Business Officer & Chief Financial Officer

Kelly Creighton Ph.D.

Executive Vice President of Chemistry, Manufacturing & Controls

Gary F. Talarico

Executive Vice President of Operations

Nikolas Burlew

Executive Vice President of Quality Assurance

Myron Z. Holubiak

Co-Founder & Executive Vice Chairman

Management

Dhananjay G. Wadekar

Senior Vice President of Business Strategy

Ilanit Allen

Vice President of Investor Relations & Corporate Communications

Myron S. Czuczman M.D.

Executive Vice President & Chief Medical Officer

Jaime BartushakCFO

Chief Business Officer & Chief Financial Officer

Kelly Creighton Ph.D.

Executive Vice President of Chemistry, Manufacturing & Controls

Gary F. Talarico

Executive Vice President of Operations

Nikolas Burlew

Executive Vice President of Quality Assurance

Myron Z. Holubiak

Co-Founder & Executive Vice Chairman

Total 8 executives

CTXR Frequently asked questions

What is Citius Pharmaceuticals, Inc. (CTXR) Stock Price?

Current stock price of Citius Pharmaceuticals, Inc. (CTXR) stock is $0.580. The stock price is +1.83% higher in the session. The intraday range can be seen from this page. Volume of Citius Pharmaceuticals, Inc. (CTXR) stock is 209.47K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Citius Pharmaceuticals, Inc. (CTXR) stock price going up or down today?

The stock price of Citius Pharmaceuticals, Inc. (CTXR) can change with earnings, company news, and overall market sentiment. Citius Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Citius Pharmaceuticals, Inc. stock expensive at its current price?

Whether Citius Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for CTXR on this page is -0.34. EPS on this page is -1.68. Compare those figures with peers and growth expectations before deciding if the current Citius Pharmaceuticals, Inc. price is justified.

How has the stock price of Citius Pharmaceuticals, Inc. (CTXR) performed historically?

Historical performance for Citius Pharmaceuticals, Inc. (CTXR) is shown on the price chart on this page. Review multi-period moves alongside volume to see how CTXR reacted to past earnings and market events.

Should I buy Citius Pharmaceuticals, Inc. (CTXR) stock, at this price?

Buying Citius Pharmaceuticals, Inc. (CTXR) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.